CME Test and Credit Request

"Click" on the single best answer for each question. At the end of the test, "click" on submit answers for checking." The answers to 70% or more of the questions must be correct in order to receive credit.

If fewer than 70% of the questions are answered correctly, the questions that were not answered correctly will be noted in red. Review the CME content related to those topics and retake the test.

If 70% or more of the questions are answered correctly, the correct and incorrect answers for all questions will be shown along with explanations of the basis for the correct answer. The link to register and receive credit is shown at the end of the items and explanations.

1. For non-valvular atrial fibrillation, which of the following oral anticoagulants has once daily dosing?
A. Eliquis® (apixaban)
B. Pradaxa® (dabigatran)
C. Xarelto® (rivaroxaban)
D. Savaysa® (edoxaban)
E. both C and D

2. Which of the following oral anticoagulants must be stored in its original packaging?
A. Eliquis® (apixaban)
B. Pradaxa® (dabigatran)
C. Xarelto® (rivaroxaban)
D. Savaysa® (edoxaban)

3. What is the recommended duration of warfarin therapy for a patient with a DVT provoked by surgery or transient/reversible risk factors?
A. 3 months
B. 6 months
C. 12 months

4. A 77 year old female with hypertension presents with atrial fibrillation. What would her CHA2DS2-VASc score be?
A. 4
B. 3
C. 2
D. 1

5. What is the typical warfarin starting dose for most relatively healthy atrial fibrillation patients?
A. 2.5 mg
B. 5 mg
C. 7.5 mg
D. 10 mg

6. Warfarin patients with mechanical heart valves, atrial fibrillation or VTE at low risk for thromboembolism generally do not need to be bridged with low molecular weight heparin around procedures/operations.
True
False

7. Which of the following types/locations of VTE may not require anticoagulation?
A. Acute isolated distal DVT of leg without severe symptoms or risk factors for extension
B. Acute proximal DVT of the leg with significant swelling and pain
C. Subsegmental PE without proximal DVT or risk factors for recurrence
D. All of the above
E. Both A and C

8. Which of these oral anticoagulants is contraindicated in atrial fibrillation patients with CrCL > 95 mL/min?
A. Eliquis® (apixaban)
B. Pradaxa® (dabigatran)
C. Xarelto® (rivaroxaban)
D. Savaysa® (edoxaban)

9. What are the main differences between warfarin and the target-specific oral anticoagulants (DOACs)?
A. Intracranial bleeding is less common in patients taking DOACs
B. Warfarin requires regular blood draws to monitor level of anticoagulation while DOACs do not
C. Warfarin has numerous drug-drug interactions while DOACs have fewer drug-drug interactions
D. Warfarin can be used in patients with mechanical heart valves while DOACs should not be used in that patient population.
E. All of the above

10. According to the AHA/ACC/HRS guidelines for atrial fibrillation, a provider for a patient with a CHA2DS2-VASc score of 2 should:
Prescribe an anticoagulant
Consider prescribing an anticoagulant or aspirin
Not prescribe an antithrombotic
None of the above

11. Due to the short half-life in DOACs, teaching patients to try not to miss doses is a very important topic to cover.
True
False

12. Patients on a DOAC do not need peri-procedural bridging.
True
False

13. Patients taking warfarin are at increased risk of GI bleeding compared to patients taking DOACs.
True
False

14. DOACs are the anticoagulant of choice for a non-cancer patient with a PE or lower extremity DVT.
True
False